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We assessed the relative contribution of the mitochondrial
respiratory chain and NADPH (nicotinamide adenine
dinucleotide phosphate) oxidase to deoxycorticosterone
acetate (DOCA)-salt hypertension in mice. The daily mean
arterial pressure was monitored by radiotelemetry in
DOCA-salt-treated mice given vehicle or the mitochondrial
respiratory chain complex I inhibitor rotenone. This
treatment produced remarkable attenuation of DOCA-salt
hypertension. Similar results were obtained with other
inhibitors of mitochondrial function, including
5-hydroxydecanoate (specific for mitochondrial potassium-
ATP channels), benzylguanidine (complexes I and III), and the
cell-permeable manganese tetrakis (4-benzoic acid)
porphyrin (a mimic of mitochondrial superoxide dismutase).
In parallel with the blood pressure-lowering effect of
rotenone, the DOCA-salt-induced increases in urinary
8-isoprostane excretion and in reactive oxygen species
production of isolated kidney mitochondria were both
significantly attenuated. Conversely, the DOCA-salt-induced
reduction of urinary nitrate/nitrite excretion was significantly
elevated. Following DOCA-salt treatment, mice deficient in
NADPH oxidase subunits gp91phox or p47phox exhibited a
partial attenuation of the hypertensive response at early but
not later time points. Thus, the mitochondrial respiratory
chain is a major source of oxidative stress in DOCA-salt
hypertension, whereas NADPH oxidase may have a relatively
minor role during the early stage of hypertension.
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The association between oxidative stress and hypertension
has been well established.1,2 Oxidative stress is found in
almost all models of hypertension, and antioxidant treat-
ments lower blood pressure (BP).2 The mechanism of the
prohypertensive action of oxidative stress primarily involves
superoxide (O2
.)-mediated nitric oxide (NO) inactiva-
tion that leads to the diminished NO availability in the
vasculature and the kidney.3 In addition, a product of the
oxidative stress-mediated peroxidation of arachidonic acid,
F2-isoprostane, also accounts for enhanced vascular activity
through activation of thromboxane receptors.4,5
It is of great significance to identify the source of oxidative
stress in animal models of hypertension. The rodent model of
deoxycorticosterone acetate (DOCA)-salt hypertension is a
widely used animal model of steroid and salt-sensitive
hypertension. This model exhibited severe hypertension
associated with aortic and renal O2
. production as well as
renal monocyte/macrophage infiltration.6,7 The source of
oxidative stress in this model, as in many other animal
models of hypertension, is still incompletely understood.
Increased aortic NADPH (nicotinamide adenine dinucleotide
phosphate) oxidase activity and decreased aortic copper/zinc
superoxide dismutase activity have been reported in the
DOCA-salt hypertensive rat.8 Treatment with NADPH
oxidase inhibitor, apocynin, in this model, reduced aortic
O2
. production and induced a varying degree of BP-lowering
effects.6,9 This finding calls for a need to define the role of
NADPH oxidase subunits and also to identify other sources
of oxidative stress than NADPH oxidase. Neither the
treatment with the NO synthase inhibitor, N-nitro-L-
arginine, nor the xanthine oxidase inhibitor, allopurinol,
affected hypertension or aortic O2
. production in DOCA-salt
rats,6 thus ruling out the contribution from uncoupled
endothelial NO synthase and xanthine oxidase. By tail-cuff
plethysmography, mice deficient in either p47phox or gp91phox
exhibit blunted hypertensive responses to DOCA-salt treat-
ment, providing further support of the involvement of
NADPH oxidase.10,11
On the other hand, there is growing evidence supporting
mitochondrial respiratory chain as an important source of
oxidative stress in normal and pathological states.12–14
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Recently, in DOCA-salt rats, endothelin receptor type A
antagonism lowered BP and normalized mitochondrial
reactive oxygen species (ROS) production without affecting
NADPH oxidase activity, representing indirect evidence for
the involvement of mitochondrial-derived ROS.15 This study
was undertaken to employ telemetry to assess the relative
importance of mitochondria respiratory chain versus
NADPH oxidase in DOCA-salt-induced hypertension.
RESULTS
Effect of NADPH oxidase deficiency on the progression of
hypertension
The baseline mean arterial pressure (MAP) was lower in both
p47phox/ and gp91phox/Y mice than in their wild-type
(WT) controls (WT: 108±2mmHg; p47phox/ 98±2
mmHg, Po0.05; gp91phox/Y: 101±3mmHg, Po0.05).
A 2-week DOCA-salt treatment induced significant increases
in MAP in all three strains of mice. Figure 1 shows the BP
response as a change from the baseline. Interaction between
mouse strain and day of treatment indicated a different
pattern of increase in MAP over treatment day between
WT and either strain of the null mice (Po0.05, repeated
measures analysis of variance). When compared with the
WT control, there was a partial attenuation of the increases
in both p47phox/ and gp91phox/Y mice within the first
2 or 3 days of DOCA-salt treatment but not at later times
(Figure 1).
Effect of NADPH oxidase deficiency on systemic oxidative
stress
Urinary 8-isoprostane levels were lower in p47phox/ mice
than in WT controls, but comparable in gp91phox/Y mice
and WT controls. In parallel with the level of MAP, urine
8-isoprostane increased in all three strains of mice following
DOCA-salt treatment (Figure 2). The increases in urinary
8-isoprostane levels in WT, p47phox/, and gp91phox/Y mice
in response to DOCA-salt were 4.6-fold, 4.1-fold, and
4.5-fold (P40.05), respectively.
Effect of rotenone and other inhibitors on DOCA-salt
hypertension
We examined the effect of the mitochondrial respiratory
chain complex I inhibitor rotenone on DOCA-salt hyperten-
sion in WTmice. Daily MAP was monitored by telemetry. On
the second day of DOCA-salt treatment, MAP in the vehicle-
treated mice increased from 110±1.3 to 138±2.0mmHg,
which remained roughly constant throughout the entire
experimental period. Rotenone treatment induced an im-
mediate and significant reduction of MAP; MAP decreased
from 144±4 to 114±3mmHg (n¼ 6, Po0.01) at the end of
the treatment (Figure 3a). To validate the effect of rotenone,
we used several other inhibitors that reduce mitochondrial
oxidative stress through diverse mechanisms. 5-hydroxy-
decanoate (5-HD) is a specific mitochondrial ATP-sensitive
potassium channel inhibitor that inhibits mitochondrial
oxidative stress via reduction of the mitochondrial inner
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Figure 1 |Radiotelemetric determination of the hypertensive response to deoxycorticosterone acetate (DOCA)-salt treatment in
wild-type (WT; n¼ 8), gp91phox/Y (n¼ 6), and p47phox/ (n¼ 6) mice. Shown is the change of mean arterial pressure (MAP) from the
baseline. *Po0.05 vs WT for the corresponding period.
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Figure 2 |Determination of 24-h urine output of 8-isoprostane
in deoxycorticosterone acetate (DOCA)-salt-treated wild-type
(WT; n¼ 8), gp91phox/Y (n¼ 6), and p47phox/ (n¼ 6) mice.
Urinary 8-isoprostane was measured by enzyme immunoassay
(EIA). :Po0.05 and *Po0.01 vs Control in the same strain;
#Po0.01 vs WT DOCA-salt.
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membrane potential.16–18 Benzylguanidine (BG), an analog of
the mitochondrial inhibitor m-iodobenzylguanidine, inhibits
complexes I and III.19–23 A cell-permeable manganese (III)
tetrakis (4-benzoic acid) porphyrin (MnTBAP) scavenges
mitochondrial ROS, possibly by mimicking mitochondrial
superoxide dismutase.24–27 Like rotenone, 5-HD, BG, and
MnTBAP all effectively lowered BP in DOCA-salt-treated
mice (Figure 3b–d). Interestingly, none of these compounds
affected baseline MAP in normotensive mice. MAP values
(in mmHg) before and after a 5-day drug treatment were
as follows: before rotenone 100.5±5.2 vs after rotenone
103.5±5.5 (n¼ 4 in each group, P40.05); before 5-HD
101.0±2.7 vs after 5-HD 99.3±3.3 (n¼ 3 in each group,
P40.05); before BG 98.0±1.7 vs after BG 96.7±0.9 (n¼ 3 in
each group, P40.05); before MnTBAP 100.0±3.4 vs
after MnTBAP 101.0±3.6 (n¼ 4 in each group, P40.05).
Table 1 shows sodium intake in various groups. None of
the mitochondrial inhibitors had a significant effect on
sodium intake.
To verify the specificity of the mitochondrial inhibitors,
we performed an assay for NADPH oxidase activity in the
kidney homogenates from DOCA-salt-treated mice in the
presence and absence of the NADPH oxidase inhibitor
apocynin or mitochondrial inhibitors such as MnTBAP,
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Figure 3 |Radiotelemetric monitoring of mean arterial pressure (MAP). Wild-type mice were treated with deoxycorticosterone
acetate (DOCA)-salt and on day 4 they were randomly divided to receive vehicle, (a) rotenone (ROT), (b) 5-hydroxydecanoate (5-HD),
(c) benzylguanidine (BG), or (d) manganese tetrakis (4-benzoic acid) porphyrin (MnTBAP) for 5–8 days. *Po0.01 vs DOCA-salt alone.
#Po0.05 vs the baseline values on day 4. DOCA-salt alone: n¼ 6; ROT: n¼ 6; 5-HD: n¼ 5; BG: n¼ 3; MnTBAP: n¼ 4.
Table 1 | Sodium intake (mmol per 24 h)
Day 0 Day 7 Day 12
Control 0.33±0.02 0.41±0.03 0.35±0.02
DOCA-salt 0.43±0.02 3.20±0.36 3.09±0.41
DOCA-salt + ROT 0.39±0.01 3.01±0.08 3.02±0.31
DOCA-salt + BG 0.32±0.02 3.13±0.30 3.21±0.28
DOCA-salt + 5-HD 0.51±0.11 3.73±0.27 3.72±0.28
Abbreviations: BG, benzylguanidine; DOCA, deoxycorticosterone acetate; 5-HD,
5-hydroxydecanoate; ROT, rotenone.
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rotenone, 5-HD, or BG. The data indicated that apocynin
effectively inhibited NADPH oxidase activity, but mitochon-
drial inhibitors, including MnTBAP, rotenone, 5-HD, and
BG, had no effect (Figure 4).
Effect of rotenone on urinary excretion of 8-isoprostane and
nitrogen oxide (NOx)
Urine 8-isoprostane and NOx levels were determined by
enzyme immunoassay and the Greiss method, respectively.
DOCA-salt elevated the urine output of 8-isoprostane from
275.47±44.65 to 1654.97±316.15 pg per 24 h, which was
reduced to 826.04±141.24 pg per 24 h after rotenone
treatment (Figure 5a). Conversely, DOCA-salt decreased
urine NOx output from 466.73±84.14 to 68.30±
15.17 pmol/g, which was restored to 38.11±44.53 pmol per
24 h by rotenone treatment (Figure 5b).
Effect of rotenone on mitochondrial ROS production
To evaluate the mitochondrial-derived ROS, we performed
two independent assays—luminal- or isoluminol-enhanced
chemiluminescence and protein carbonyl assay—on kidney
mitochondria isolated from DOCA-salt mice receiving
vehicle or rotenone. DOCA-salt treatment induced an
B2.5-fold increase in both mitochondrial ROS production
(Figure 5c) and protein carbonyls (Figure 5d), both of which
were remarkably inhibited by rotenone. To evaluate the
purity of the mitochondrial preparation, we compared the
abundance of gp91phox, p47phox, and cytochrome b between
the supernatant and the mitochondrial fraction. As expected,
mitochondrial protein cytochrome b was detected predomi-
nantly in the mitochondrial fraction, whereas cytosolic
protein p47phox and membranous protein gp91phox were
mostly in the supernatant (Figure 6). This supernatant was
prepared at low centrifugation (3500 g) and expected to
contain both cytosolic and membranous fractions.
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Figure 5 | Effects of rotenone on systemic and mitochondrial oxidative stress in deoxycorticosterone acetate (DOCA)-salt-treated
mice. (a) The 24-h urine output of 8-isoprostane; (b) the 24-h urine output of nitrate/nitrite (NOx); (c) determination of reactive oxygen
species (ROS) generation from isolated mitochondria using the enhanced luminal or isoluminol chemiluminescence; and (d) determination
of the protein carbonyls from isolated mitochondria. *Po0.01 vs Control; #Po0.01 vs DOCA-salt alone.
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Figure 4 | Effects of apocynin and mitochondrial inhibitors
on nicotinamide adenine dinucleotide phosphate (NADPH)
oxidase activity. The kidneys from deoxycorticosterone acetate
(DOCA)-salt-treated mice were homogenized and NADPH
oxidase activity was assessed in the presence and absence of
apocynin or the mitochondrial inhibitors. *Po0.01 vs control,
n¼ 6 for each group.
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Effect of rotenone and NADPH oxidase subunit deficiency on
DOCA-salt-induced albuminuria
Proteinuria is an important feature of DOCA-salt-induced
renal injury. Therefore, we compared the effects of rotenone
and NADPH oxidase subunit deficiency on urinary albumin
excretion in DOCA-salt-treated mice. DOCA-salt elevated
the urine albumin excretion from 28.24±4.83 to 145.54±
15.64 mg per 24 h (Po0.01), which was reduced to 90.80±
15.55 mg per 24 h (Po0.01) by rotenone treatment (Figure
7a). In sharp contrast, DOCA-salt-induced albuminuria was
not inhibited, but was modestly aggravated in both
gp91phox/Y and p47phox/ mice (baseline: 26.18±1.87 in
WT, 18.79±3.12 in p47phox/, and 15.55±2.23 mg per 24 h
in gp91phox/Y; DOCA-salt: 150.67±14.18 in WT,
172.80±12.11 in p47phox/, and 196.34±12.14 mg per
24 h in gp91phox/Y; Figure 7b).
The toxicity profile of rotenone
The toxicity of rotenone was assessed by monitoring changes
in body weight and performing blood biochemical analysis,
tissue histological analysis, and terminal deoxynucleotidyl
transferase-mediated dUTP nick end labeling (TUNEL) assay.
Body weight was monitored daily before and during the
induction of hypertension. After 2 weeks of DOCA-salt
treatment, body weight increased in the vehicle group from
29.02±1.18 to 32.03±1.24 g (Po0.01), whereas the body
weight of the rotenone group remained roughly constant
(28.87±1.17 vs 28.18±1.73 g, P40.05). Plasma blood urea
nitrogen, creatinine, lactate dehydrogenase, and creatine
kinase-MB were determined, and none of these parameters
was significantly affected by rotenone treatment (Table 2).
Hematoxylin and eosin staining of major internal organs,
including brain, heart, liver, and kidney, did not reveal
obvious abnormalities associated with rotenone treatment
(Figure 8), nor did TUNEL assay on the kidney. The numbers
of apoptotic cells in the control, DOCA-salt-alone, and
DOCA-salt plus rotenone groups were 1.02±0.18,
1.22±0.19, and 1.27±0.22 per field (P40.05), respectively.
Body weights were determined before and 5 days after
treatment with 5-HD, BG, or MnTBAP and were not
significantly affected by any of these compounds (before
5-HD 30.025±0.62 vs after 5-HD 29.65±1.3 g, n¼ 4 in each
group, P40.05; before BG 29.8±0.1.2 vs after BG
29.6±0.55 g, n¼ 3 in each group, P40.05; before MnTBAP
27.66±1 vs after MnTBAP 27.19±0.75 g, n¼ 4 in each
group, P40.05).
Effect of rotenone and apocynin on aldosterone-induced ROS
production in cultured vascular smooth muscle cells (VSMCs)
We attempted to use a cell culture model to compare the
direct effects of rotenone and the NADPH oxidase inhibitor
apocynin on aldosterone-induced ROS production. In cultured
VSMCs, exposure for 40min to aldosterone in the range of
100–1000 nmol/l dose dependently induced ROS production
as assessed by 20,70-dichlorofluorescein fluorescence (Figure 9a).
Based on this observation, 1000 nmol/l was used for
subsequent experiments to determine the time course of
ROS production and also the effects of rotenone and
apocynin. The ROS production in response to aldosterone
treatment was detected as early as 10min and remained
elevated over the next 40-min period. The stimulation
of ROS production was normalized by 10 mmol/l rotenone
at all time points and was partially attenuated by 100 mmol/l
apocynin only at 10min but not at later time points
(Figure 9b).
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Figure 6 | Evaluation of the purity of the mitochondrial
preparation. The presence of (a) p47phox, (b) gp91phox, and (c)
cytochrome b (cyt b) in the supernatant and the mitochondrial
fraction. The pelleted mitochondria and the supernatant were
isolated from the mouse kidney, loaded in the same amount, and
analyzed for gp91phox, p47phox, and cyt b using immunoblotting.
Shown are representatives of 2 to 3 experiments.
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Figure 7 | Effects of rotenone and gp91phox and p47phox deficiency on deoxycorticosterone acetate (DOCA)-salt-induced albuminuria.
(a) Urinary albumin excretion in control, DOCA-salt treated, or DOCA-salt þ rotenone-treated wild-type (WT) mice; (b) urinary albumin
excretion in vehicle and rotenone-treated wild type, gp91phox/Y, and p47phox/ mice. *Po0.01 vs Control; #Po0.01 vs DOCA-salt alone.
(a) n¼ 6 in each group. (b) WT: n¼ 8; gp91phox/Y: n¼ 6; p47phox/: n¼ 6.
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DISCUSSION
The mitochondrial respiratory chain and NADPH oxidase
have emerged as major sources of ROS production.28,29 In the
present study, using a radiotelemetric technique, we critically
assessed the relative importance of the two types of ROS
sources in a mouse model of DOCA-salt hypertension.
Treatment with the mitochondrial complex I inhibitor
rotenone induced a marked reduction of MAP associated
with parallel attenuation of systemic oxidative stress,
mitochondrial ROS production, and albuminuria. Several
other inhibitors that reduce mitochondrial oxidative stress
through diverse mechanisms all produced a BP-lowering
effect similar to that of rotenone. In contrast, the hyperten-
sive responses to DOCA-salt treatment in neither p47phox/
nor gp91phox/Y mice were significantly different from those
of WT controls except at the early phase in the development
of hypertension. In cultured VSMCs, rotenone effectively
prevented aldosterone-induced ROS production up to
40min, whereas the NADPH oxidase inhibitor apocynin
only inhibited it at 10min but not at later time points. These
results favor the mitochondrial respiratory chain as a major
source of oxidative stress in the mouse model of DOCA-salt
hypertension, whereas NADPH oxidase may have a relatively
minor role.
NADPH oxidase is a multicomponent enzyme comprising
the membrane-associated subunits p22phox and gp91phox and
the cytosolic subunits p47phox, p67phox, and p40phox. Among
these subunits, gp91phox and p47phox are of particular
importance, as the former contains the catalytic domain
and the latter is necessary for cytosolic subunit translocation
and for initiation of NADPH oxidase assembly. In recent
years, four homologs of gp91phox (Nox2), Nox1 (Suh et al.30)
Nox3, Nox4, and Nox5 (Lambeth29) have been identified,
whereas the homologs of p47phox have not yet been found.
The involvement of NADPH oxidase in rat models of DOCA-
salt hypertension was initially suggested through pharmaco-
logical approaches.6,9 Subsequently, mice deficient in p47phox
or gp91phox have been shown to be resistant to the
development of hypertension following DOCA-salt treat-
ment.10,11 Surprisingly, we found that the hypertensive
responses to DOCA-salt treatment in both gp91phox- and
p47phox-deficient mice remained largely intact. The exact
reason for the disparities is unclear, but it could be related
to different techniques used for measurements of BP.
In previous studies,10,11 arterial pressure was measured by
Table 2 | Plasma BUN, creatinine, LDH, and CK-MB
BUN (mg/dl)
Creatinine
(mg/dl) LDH (U/l) CK-MB (U/l)
Control 13.67±1.45 0.23±0.03 1195.33±172.58 25.07±2.32
DOCA-salt 10.67±1.20 0.25±0.04 1351.00±279.58 27.07±5.97
DOCA-salt + ROT 13.00±1.58 0.22±0.03 1198.50±129.56 26.33±2.79
Abbreviations: BUN, blood urea nitrogen; CK-MB, creatine kinase-MB; DOCA,
deoxycorticosterone acetate; LDH, lactate dehydrogenase; ROT, rotenone.
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Figure 8 | Effect of rotenone on tissue histology. Wild-type (WT) mice were treated as in Figure 3 and tissue sections were hematoxylin
and eosin (HE) stained. Shown are representative sections of (a–c) brain, (d–f) heart, (g–i) liver, and (j–l) kidney from (a, d, g, l) control,
(b, e, h, k) deoxycorticosterone acetate (DOCA)-salt, and (c, f, i, l) DOCA-salt with rotenone-treated mice. Micrographs were taken at  200
magnification.
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tail-cuff plethysmography, a noninvasive measure that
reports only systolic pressure and requires restraint and
tail-cuff inflation that introduces stress. In the present study,
however, MAP was monitored by radiotelemetry, which is
not associated with the limitations of tail-cuff method.
Second, the aforementioned disparities may be related to
differences in experimental protocols for generating mouse
models of DOCA-salt hypertension. Uninephrectomy was
performed and a standard solid chow diet used in the
previous two studies, whereas we did not perform unine-
phrectomy but used high-salt diets (1.5% NaCl in the gelled
formulation). The use of the gelled formulation of a high-salt
diet in conjunction with saline as the drinking fluid in the
present study may make sodium loading more efficient.
Third, Landmesser et al.31 only presented the absolute BP
values in WT and p47phox/ mice after DOCA-salt
treatment, whereas we showed the change of MAP from
the baseline. As p47phox/ mice had low baseline BP, the
magnitude of the change of BP will be more informative. Of
note, the involvement of Nox4 cannot be excluded in our
models because the activity of Nox4 does not require known
cytosolic oxidase proteins or the GTPase Rac.32 Unlike other
Nox proteins, Nox4 produces large amounts of hydrogen
peroxide constitutively.32
Mitochondria are important cellular organelles for
oxidative phosphorylation, the energy production pathway
that is associated with the generation of the by-product
superoxide anion (O2
.). Approximately 0.4–4% of the
molecular oxygen (O2) consumed by the mitochondria is
reduced by a single electron transfer from the initial steps of
the electron transport chain to form O2
..33–35 There is a
growing appreciation of the mitochondria respiratory chain
as an important source of oxidative stress under states of
aging, diabetes, and so on.14,36–40 Compared with an
overwhelming understanding about NADPH oxidase in
hypertension, scant information is available about the role
of mitochondria in this disease process. The mitochondrial
complex I inhibitor rotenone is widely used to block
mitochondrial-derived ROS production in various cell
types.41 Using radiotelemetric technique, we provide new
evidence that the inhibition of mitochondrial ROS produc-
tion by rotenone induced a striking BP-lowering effect in the
mouse model of DOCA-salt hypertension. This effect is
associated with the suppression of systematic oxidative stress
and the almost compete normalization of ROS production
from isolated kidney mitochondria, and with the restoration
of NO levels. These observations support the notion that the
BP-lowering effect of rotenone may be related to inhibition of
mitochondrial ROS production.
Given the important role of mitochondria in energy
production, rotenone is suspected to induce some degree of
toxicity. An issue arises as to whether the BP-lowering effect
is secondary to rotenone-induced organ damage. Therefore,
we performed histological analysis of several internal organs
as well as a TUNEL assay on the kidney. These assays did not
reveal obvious tissue injuries associated with rotenone
treatment. During 2 weeks of DOCA-salt treatment, the
body weight of the animals increased B3 g (B10% body
weight), far exceeding natural growth in adulthood, a
possible sign of fluid retention. In contrast, body weight
gain was completely prevented by rotenone treatment. This
phenomenon may reflect lack of fluid retention following
rotenone treatment. A study from the National Toxicology
Program reported that rotenone treatment for 14 days at
doses ofX1200 p.p.m. induced decreases in body weight gain
in rats but not in mice, and that this dose range was well
tolerated for up to 2 years.42 Overall, the relatively low dose
and short duration of rotenone treatment in the present
study was unlikely to have produced significant toxicities,
which may account for the remarkable BP-lowering effect of
the compound.
Considering the specificity issue of rotenone, we used several
other inhibitors that interfere with various steps of mitochon-
drial ROS production. Mitochondrial superoxide production
occurs in complexes I and III of the electron transport chain.43
This process is modulated by the mitochondrial inner mem-
brane potential, which is determined by potassium influx
through the mitochondrial ATP-sensitive potassium channel.44
A specific mitochondrial ATP-sensitive potassium channel inhi-
bitor, 5-HD, inhibits mitochondrial oxidative stress, whereas the
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Figure 9 | Effect of rotenone and apocynin on the aldosterone-
induced reactive oxygen species (ROS) generation in vascular
smooth muscle cells (VSMCs). (a) Confluent VSMCs in 96-well
plates were treated with the indicated dose (100–1000 nmol/l) of
aldosterone for 40min, or (b) pretreated with apocynin (100mmol/l)
or rotenone (10 mmol/l), and then stimulated by 1000 nmol/l
aldosterone for the indicated time in the presence of DCF.
Fluorescence was quantified using FLUOstar OPTIMA (BMG
Labtech, Cary, NC). *Po0.05, **Po0.01 vs control; :Po0.05,
#Po0.01 vs aldo-treated VSMCs. DCF, 20,70-dichlorofluorescein.
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channel openers increase it.16–18 BG is an analog of the
mitochondrial inhibitor m-iodobenzylguanidine, which in-
hibits complexes I and III.19–23 MnTBAP belongs to a class of
catalytic antioxidants. A sizable literature shows that
MnTBAP is capable of scavenging mitochondrial ROS,
possibly by mimicking mitochondrial superoxide dismu-
tase.24–27 Like rotenone, 5-HD, BG, and MnTBAP all
effectively lowered BP in DOCA-salt-treated mice. The
consistent results obtained with various mitochondrial
inhibitors have substantiated the role of mitochondrial ROS
in mediating DOCA-salt hypertension.
Another possible explanation for our findings is that
different oxidant-producing systems, namely, NADPH oxi-
dase and the mitochondrial respiratory chain, act in concert
to sustain ROS production at different stages of the
hypertension development. Landmesser et al.11 suggest that
the initial activation of NADPH oxidase may lead to greater
ROS production later from other sources, such as NO
synthase uncoupling. The activation of NADPH oxidase may
trigger ROS production from the mitochondrial respiratory
chain in addition to NO synthase uncoupling. Along this
line, we found that in cultured VSMCs, apocynin partially
attenuated the initial rise of aldosterone-induced ROS
production. In this cell culture model, rotenone almost
completely blocked the ROS production, again supporting
the mitochondrial respiratory chain as a dominant source
of oxidative stress during aldosterone excess. The two
oxidant-producing systems may interact to initiate the ROS
generation in response to mineralocorticosteroid excess and
the nature of such interaction needs to be explored in future
studies.
The present study is limited in the inability to address
whether oxidative stress is a cause or a consequence of
hypertension. A temporal analysis of oxidative stress levels
might be helpful, although it cannot establish causality. This
experiment was not performed because of technical difficulty.
Instead, this issue has been partially addressed by the in vitro
study showing that rotenone rapidly and effectively blocked
aldosterone-induced ROS generation. However, the in vitro
data are only suggestive of, but do not prove, a cause–effect
relationship.
In summary, we used telemetry in the present study to
thoroughly examine the relative contribution of the mito-
chondrial respiratory chain, in comparison with that of
NADPH oxidase, to DOCA-salt hypertension in mice. The
hypertensive response to DOCA-salt largely remains intact in
both gp91phox- and p47phox-deficient mice except at the early
phases of the hypertension development. In contrast,
pharmacological suppression of mitochondrial ROS levels
produces a marked BP-lowering effect. Our results suggest
that the mitochondrial respiratory chain may represent a
major source of ROS production in DOCA-salt hypertension,
whereas NADPH oxidase may have a relatively minor role.
Future studies are needed to critically evaluate the relative
importance of the two ROS-generating systems in other
forms of hypertension. A better understanding of the source
of oxidative stress in animal models of hypertension may be
helpful for the development of novel antihypertensive therapies.
MATERIALS AND METHODS
Animals
The entire experimental cohorts of male mice deficient in gp91phox
(gp91phox/Y, stock no. 002365) and p47phox (p47phox/, stock no.
004742) and WT control (inbred C57BL/6) mice at the age of 3 to 4
months (25–30 g) were obtained from Jackson Laboratories
(Bar Harbor, ME). The genotyping of the mutant strains has been
validated by the vendor. No breeding was conducted at the
University of Utah. gp91phox-deficient mice were originally pro-
duced from the laboratory of MC Dinauer,45 and p47phox-deficient
mice carry a spontaneous mutation of the Ncf1 gene, which leads to
a complete loss of p47phox protein.46 Both strains of mice were
backcrossed at least 8 to the C57BL/6 background at Jackson
Laboratories. All mice were housed in an air-conditioned room with
a 12-h light/dark cycle. All procedures and protocols were in
accordance with the guidelines set by the laboratory animal care
committee at the University of Utah.
Animal experimental protocols
Protocol 1: This protocol was designed to evaluate the role of
NADPH oxidase subunits in DOCA-salt hypertension. The radio-
telemetric device was implanted into gp91phox–/Y (n¼ 6), and
p47phox/ (n¼ 6) and WT (n¼ 8) mice through catheterization
of the carotid artery (model no. TA11PA-C20; DSI, St Paul, MN) as
previously described.47 After allowing 1 week for recovery, baseline
MAP was collected. A slow-release (21-day) 50mg DOCA pellet was
then implanted subcutaneously through a midscapular incision.
Following the surgery, animals received 1.5% NaCl in gelled diets
(TestDiet, cat no. 0007551, Richmond, IN) and 1% NaCl in drinking
water. The gelled diets were made as previously described.48 Daily
MAP was recorded as mean values of 4-h recordings from 0900 to
1300 hours as previously described.47 Mice were placed in metabolic
cages (Hatteras Instruments, Cary, NC) for 24-h urine collections
before and at the end of experiments.
Protocol 2: This protocol was designed to evaluate the
involvement of mitochondrial oxidative stress in DOCA-salt
hypertension in mice. The WT mice were implanted with the
radiotelemetric device and treated with DOCA-salt as described
above. After stabilization of BP for 4 days, the mice were
randomized to receive vehicle, rotenone (600 p.p.m. in a gelled
diet), 5-HD (10mg/kg/day, intraperitoneal), BG (10mg/kg/day,
intraperitoneal), or MnTBAP (15mg/kg/day, intraperitoneal). All
compounds were purchased from Sigma (St Louis, MO) unless
otherwise specified.
BP and heart rate measurements
The telemetric device was implanted into mice through catheteriza-
tion of the carotid artery, according to the manufacturer’s
instructions (model no. TA11PA-C20; DSI). Animals were allowed
to recover from surgery for at least 1 week before DOCA-salt
treatment. Daily MAP and heart rate were monitored every 20min
from 0900 to 1300 hours. The daily value of MAP and heart rate in
each animal is the mean value of the 4-h recording.
Blood sample analysis
The plasma samples were diluted 1:50 with distilled water before
assays. Plasma blood urea nitrogen, creatinine, lactate dehydrogenase,
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and creatine kinase isoenzyme MB were measured using an
autoanalyzer (Victors 750, Johnson & Johnson, Rochester, NY).
Urine analysis of albumin, 8-isoprostane, and NOx
Urinary concentrations of albumin and 8-isoprostane were determined
using enzyme immunoassay kits from Exocell (Philadelphia, PA) and
Cayman (Ann Arbor, MI), respectively. Before 8-isoprostane enzyme
immunoassay, urine samples were purified using an 8-isoprostane
affinity column (Cayman Chemicals model no. 416358). Urinary
NOx concentrations were determined using the Griess method
(nitrate/nitrite colorimetric assay kit; Cayman Chemicals). For all
the assays, samples were run in duplicate and results averaged.
Assays for mitochondrial oxidative stress
Mitochondria from the kidneys of DOCA-salt group and DOCA-salt
plus rotenone group were isolated using a kit from Sigma (MITO-
ISO1; Sigma Chemical) according to the manufacturer’s protocol.
Briefly, whole kidney was homogenized in Extraction Buffer A
(50mmol/l HEPES, 1 M mannitol, 350mmol/l sucrose, and 5mmol/l
EGTA, pH 7.5) and centrifuged twice at 1200 g for 5min to pellet
unbroken cells, nuclei, and large debris. The aqueous phase was
carefully transferred to a new tube and centrifuged twice at 3500 g
for 10min to pellet the mitochondria. The isolated mitochondria
were resuspended in storage buffer and protein concentration was
determined by Coomassie reagent. The rate of ROS generation by
intact mitochondria (0.50–0.60mg total protein in 1ml of assay)
was detected by enhancer-amplified luminal chemiluminescence
using superoxide/reactive oxygen species determination kit
(WPI, Sarasota, FL) according to the manufacture’s protocol.
Luminescence was measured every 1.8 s for 3min.
Assay for mitochondrial protein carbonyls
Mitochondrial protein carbonyls were determined by derivatization
with 2,4-dinitrophenylhydrazine, according to the report from
Levine et al.36 Carbonyl content was measured spectrophotome-
trically at 366 nm. Results were expressed as nanomoles carbonyl per
mg protein.
Assay for NADPH oxidase activity
The homogenates of the kidney from DOCA-salt- treated mice were
prepared in Krebs solution using a glass-to-glass homogenizer, and
NADPH oxidase activity was measured as previously reported.49 The
activity was expressed as arbitrary units per mg protein.
Immunoblotting
The cytosolic and mitochondrial proteins (30 mg each) were
denatured in boiling water for 10min, separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and transferred onto
nitrocellulose membranes. The blots were blocked overnight with
5% nonfat dry milk in Tris-buffered saline, followed by incubation
for 1 h with mouse anti-gp91phox or anti-p47phox monoclonal anti-
bodies (BD Biosciences, San Jose, CA) at a dilution of 1:1000. After
washing with Tris-buffered saline, blots were incubated with a goat
anti-horseradish peroxidase-conjugated secondary antibody (1:1000
dilution) and visualized with ECL kits (Amersham, Piscataway, NJ).
Histological analysis
Several internal organs including brain, heart, liver, and kidney were
fixed in 3% paraformaldehyde, embedded in paraffin, and then
sectioned (2 mm thickness). Sections were stained with hematoxylin/
eosin and examined with light microscope. Magnification of
micrographs was  200.
TUNEL assay
Cells undergoing apoptosis in the kidney were identified using an
ApopTag In Situ Apoptosis Detection Kit (Chemicon, Temecula,
CA). After being dewaxed, the tissue sections were treated with
proteinase K (20mg/ml) and incubated with equilibration buffer in a
humidified chamber for 10min at room temperature, followed
by incubation with working-strength TdT enzyme solution in a
humidified chamber at 37 1C for 1 h. The reaction was terminated by
incubation in working-strength stop/wash buffer for 10min at room
temperature. After being rinsed with phosphate-buffered saline, the
tissue sections were incubated with fluorescein isothiocyanate-
conjugated antidigoxigenin antibody in a humidified chamber for
30min at room temperature. As a positive control, slides were
treated with DNase (20Kunitz U/ml) and the slides for the negative
control were treated with buffer lacking TdT. The number of
TUNEL-positive cells was counted at 20 different fields in each
section under  200 magnification.
Cell culture
The normal human aorta VSMC line (American Type Culture
Collection (ATCC) CRL-1999, Manassas, VA) was maintained in
F12K Kaighn’s modification media containing 10mmol/l N-tris
[hydroximethyl]methyl-2-aminoethanesulfonic acid, 0.3mmol/l
L-ascorbic acid, 0.001mmol/l insulin, 0.001% transferrin, 58nmol/l
sodium selenite, 0.003% endothelial growth supplement, 1% antibiotic/
antimycotic, 1% L-glutamine, 1% HEPES, 1% non-essential amino
acids, 1% sodium pyruvate, and 10% heat-inactivated fetal calf serum.
The cells were split once a week as per ATCC recommendation and
were maintained for no more than 10 divisions.
Statistical analysis
All data are given as mean±s.e. For analysis of the hypertensive
response in Figure 1, repeated measures analysis of variance was
performed to detect an interaction (time strain). Differences
between groups in other figures were assessed by analysis of variance
and Student-Newman-Keuls post hoc test for multiple comparisons,
with a P-value o0.05 considered to be significant.
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